Marqibo (vincristine sulfate liposomal)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Generic name: vincristine sulfate liposomal
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Marqibo
Indications
The following indications are listed for Marqibo:
- Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Also known as: Ph-Negative B-Cell Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Precursor-B Acute Lymphoblastic Leukemia.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.